Mode
Text Size
Log in / Sign up

BRAF V600E/K-Mutant Melanoma

Part of Cancer

1 published article · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cancer

Related studies from across the Cancer family.

Narrowband UVB remains first-line phototherapy for vitiligo, with JAK inhibitors emerging as adjuncts
Rheumatology Sys. Review
Narrowband UVB remains first-line phototherapy for vitiligo, with JAK inhibitors emerging as adjuncts New light therapies and skin grafts offer hope for vitiligo patients
This narrative review synthesizes current evidence on phototherapy for vitiligo, highlighting narrowband UVB as the mainstay. Excimer lasers…
A review of treatments for vitiligo highlights options like narrowband ultraviolet B light, excimer therapy, and cellular grafting that may …
Meta-analysis finds modest melanoma risk increase among infertile women using fertility treatments
Oncology Meta-analysis
Meta-analysis finds modest melanoma risk increase among infertile women using fertility treatments Fertility Drugs Linked to Slight Rise in Melanoma Risk
This systematic review and meta-analysis evaluated melanoma incidence in infertile women exposed to fertility treatments compared to untreat…
A large review finds fertility drugs may raise melanoma risk slightly, but the increase is small and more research is needed.
TIL therapy and engineered viral vector immunotherapies show pooled ORR of 37.8% in advanced melanoma
Oncology Meta-analysis
TIL therapy and engineered viral vector immunotherapies show pooled ORR of 37.8% in advanced melanoma First new analysis in years shows TIL therapy response rates for advanced melanoma
This Bayesian meta-analysis synthesizes data from 13 eligible studies on TIL therapy and engineered viral vector immunotherapies for advance…
A Bayesian meta-analysis of 13 studies finds TIL therapy yields a 49% response rate in advanced melanoma, with moderate certainty for respon…
Systematic Review: Intercellular Mitochondrial Transfer in Melanoma Progression and Resistance
Oncology Sys. Review
Systematic Review: Intercellular Mitochondrial Transfer in Melanoma Progression and Resistance Mitochondrial Transfer Fuels Melanoma Resistance and Spread
This systematic review examines the role of intercellular mitochondrial transfer in melanoma. The authors find that this process contributes…
A systematic review reveals that intercellular mitochondrial transfer helps melanoma resist therapies and spread, but may also suppress tumo…
Meta-analysis finds germline LTS and somatic TERT variants are mutually exclusive in thyroid cancer and melanoma
Genetics & Precision Medicine Meta-analysis
Meta-analysis finds germline LTS and somatic TERT variants are mutually exclusive in thyroid cancer and melanoma Two different cancer drivers do not appear together in these tumors
This meta-analysis of retrospective observational cohorts examined germline long-telomere syndrome variants and somatic TERT promoter altera…
A large review of nearly 2,000 adults with thyroid cancer or melanoma found that two specific genetic changes never occur in the same tumor.
Narrative review outlines multimodal decision-making for EGFR-mutant NSCLC with leptomeningeal metastasis
Neurology Guideline
Narrative review outlines multimodal decision-making for EGFR-mutant NSCLC with leptomeningeal metastasis Doctors outline a pathway for treating lung cancer that spreads to the brain
This narrative review addresses patients with EGFR-mutant non-small cell lung cancer who develop resistance to tyrosine kinase inhibitors an…
This review outlines a clinical pathway to help physicians personalize treatment for lung cancer patients with brain spread.
Systematic review and meta-analysis of AI for melanoma risk assessment in pigmented skin lesions
Dermatology Meta-analysis
Systematic review and meta-analysis of AI for melanoma risk assessment in pigmented skin lesions AI plus doctors finds every skin cancer case in real-world settings
This systematic review and meta-analysis synthesized evidence from 17 diagnostic arms on AI, dermoscopy, and AI-assisted clinicians for mali…
When doctors used AI alongside standard skin checks, they caught every cancer case without missing any, showing a powerful new way to help p…
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Systematic review and meta-analysis on alopecia areata and skin cancer risk
Oncology Meta-analysis
Systematic review and meta-analysis on alopecia areata and skin cancer risk Alopecia areata patients may have lower risk of certain skin cancers based on new review data
This systematic review and meta-analysis synthesized eight studies on skin cancer risk in patients with alopecia areata. The analysis found …
This review found that people with hair loss might have a lower chance of getting melanoma. Other skin cancers showed a similar trend but th…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Oncology Meta-analysis
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers
Oncology FDA Approval
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers FDA approves Enhertu for several types of HER2 positive cancers.
FDA approved Enhertu for several indications including HER2-positive metastatic breast cancer, HER2-low and HER2-ultralow breast cancer, HER…
The FDA has approved Enhertu for multiple cancers, including breast, lung, stomach, and other solid tumors that have a specific protein call…
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
Oncology Meta-analysis
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…